Journal of Diabetes Investigation (Mar 2023)

New‐onset type 1 diabetes and Graves' disease after antiretroviral therapy in a patient with human immunodeficiency virus infection

  • Maho Taguchi,
  • Noriko Ihana‐Sugiyama,
  • Daisuke Shiojiri,
  • Kazuo Izumi,
  • Michi Kobayashi,
  • Noriko Kodani,
  • Ryotaro Bouchi,
  • Mitsuru Ohsugi,
  • Akiyo Tanabe,
  • Kohjiro Ueki,
  • Hiroshi Kajio

DOI
https://doi.org/10.1111/jdi.13965
Journal volume & issue
Vol. 14, no. 3
pp. 489 – 493

Abstract

Read online

Abstract Patients with human immunodeficiency virus (HIV) infection receiving antiretroviral therapy can develop autoimmune diseases, referred to as immune‐inflammatory reconstitution syndrome. Nevertheless, only a few reports on the onset of type 1 diabetes as immune‐inflammatory reconstitution syndrome are available. A 40‐year‐old Japanese man with HIV infection was initiated with antiretroviral therapy at the age of 29 years. He developed Graves' disease at 35 years and diabetes, with a hemoglobin A1c of 6.5%, and maintained insulin secretion at 38 years. His antiglutamic acid decarboxylase antibody level was >2,000 U/mL, and he was diagnosed with slowly progressive type 1 diabetes. At the age of 40 years, he was admitted to our hospital with diabetic ketosis. We retrospectively assayed his stored plasma samples for thyroid‐stimulating hormone receptor antibody and antiglutamic acid decarboxylase antibody, which showed positive conversion after initiating antiretroviral therapy, suggesting that Graves' disease and type 1 diabetes developed as a probable result of immune‐inflammatory reconstitution syndrome.

Keywords